Crossmark Global Holdings Inc. Sells 1,500 Shares of Novo Nordisk A/S (NYSE:NVO)

Crossmark Global Holdings Inc. lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 51,096 shares of the company’s stock after selling 1,500 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Novo Nordisk A/S were worth $4,395,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in NVO. Gabelli Funds LLC increased its stake in Novo Nordisk A/S by 35.7% during the 2nd quarter. Gabelli Funds LLC now owns 46,963 shares of the company’s stock worth $6,703,000 after acquiring an additional 12,363 shares during the period. Xponance Inc. increased its position in shares of Novo Nordisk A/S by 27.6% in the second quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after purchasing an additional 576 shares during the period. Marshall Wace LLP raised its stake in Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Insigneo Advisory Services LLC lifted its position in Novo Nordisk A/S by 1.0% during the second quarter. Insigneo Advisory Services LLC now owns 10,693 shares of the company’s stock worth $1,526,000 after purchasing an additional 108 shares during the period. Finally, Fred Alger Management LLC grew its stake in Novo Nordisk A/S by 38.4% during the second quarter. Fred Alger Management LLC now owns 54,493 shares of the company’s stock worth $7,778,000 after buying an additional 15,129 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent analyst reports. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $80.59 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market cap of $361.65 billion, a PE ratio of 26.08, a PEG ratio of 0.84 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The business has a 50-day simple moving average of $96.63 and a two-hundred day simple moving average of $116.04.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.